| SARS-CoV-2 infection among patients with systemic autoimmune diseases G Emmi, A Bettiol, I Mattioli, E Silvestri, G Di Scala, ML Urban, A Vaglio, ... Autoimmunity reviews 19 (7), 102575, 2020 | 182 | 2020 |
| Vascular Behçet’s syndrome: an update G Emmi, A Bettiol, E Silvestri, G Di Scala, M Becatti, C Fiorillo, D Prisco Internal and emergency medicine 14, 645-652, 2019 | 138 | 2019 |
| Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study A Bettiol, ML Urban, L Dagna, V Cottin, F Franceschini, S Del Giacco, ... Arthritis & rheumatology 74 (2), 295-306, 2022 | 103 | 2022 |
| Adalimumab‐based treatment versus disease‐modifying antirheumatic drugs for venous thrombosis in Behçet's syndrome: A retrospective study of seventy patients with vascular … G Emmi, A Vitale, E Silvestri, M Boddi, M Becatti, C Fiorillo, C Fabiani, ... Arthritis & Rheumatology 70 (9), 1500-1507, 2018 | 62 | 2018 |
| Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: a preliminary study G Di Scala, A Bettiol, RD Cojan, M Finocchi, E Silvestri, G Emmi Journal of autoimmunity 97, 108-113, 2019 | 61 | 2019 |
| The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Behçet’s disease C Fabiani, A Vitale, D Rigante, G Emmi, G Lopalco, G Di Scala, J Sota, ... Ocular immunology and inflammation, 2018 | 61 | 2018 |
| Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in … P Ruscitti, P Cipriani, V Liakouli, D Iacono, I Pantano, DPE Margiotta, ... Arthritis research & therapy 21, 1-10, 2019 | 51 | 2019 |
| The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review A Bettiol, E Silvestri, G Di Scala, A Amedei, M Becatti, C Fiorillo, ... Rheumatology international 39, 971-990, 2019 | 50 | 2019 |
| Behçet’s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects M Becatti, G Emmi, A Bettiol, E Silvestri, G Di Scala, N Taddei, D Prisco, ... Clinical & Experimental Immunology 195 (3), 322-333, 2019 | 48 | 2019 |
| Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study F Fagni, A Bettiol, R Talarico, G Lopalco, E Silvestri, ML Urban, ... Annals of the rheumatic diseases 79 (8), 1098-1104, 2020 | 47 | 2020 |
| Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: a cross-sectional study MND Di Minno, G Emmi, P Ambrosino, A Scalera, A Tufano, G Cafaro, ... International journal of cardiology 274, 1-6, 2019 | 39 | 2019 |
| Adalimumab Accounts for Long‐Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study A Bitossi, A Bettiol, E Silvestri, G Di Scala, D Bacherini, G Lopalco, ... Mediators of Inflammation 2019 (1), 1623847, 2019 | 35 | 2019 |
| Alveolar haemorrhage in ANCA-associated vasculitis: long-term outcome and mortality predictors L Quartuccio, M Bond, M Isola, S Monti, M Felicetti, F Furini, S Murgia, ... Journal of autoimmunity 108, 102397, 2020 | 31 | 2020 |
| Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab C Fabiani, A Vitale, D Rigante, G Emmi, G Lopalco, J Sota, L Vannozzi, ... Clinical Rheumatology 37, 1715-1720, 2018 | 27 | 2018 |
| Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease G Lopalco, V Venerito, P Leccese, G Emmi, L Cantarini, N Lascaro, ... Annals of the Rheumatic Diseases 78 (12), 1736-1737, 2019 | 26 | 2019 |
| A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis D Martorana, A Márquez, FD Carmona, F Bonatti, A Adorni, ML Urban, ... Journal of Allergy and Clinical Immunology 142 (5), 1662-1665, 2018 | 26 | 2018 |
| Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome E Silvestri, A Bitossi, A Bettiol, G Emmi, ML Urban, I Mattioli, G Di Scala, ... Inflammopharmacology 28, 711-718, 2020 | 24 | 2020 |
| Long‐Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis S Gentileschi, D Rigante, J Sota, G Lopalco, MG Giannotta, G Emmi, ... Mediators of Inflammation 2020 (1), 6983272, 2020 | 23 | 2020 |
| Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective … P Ruscitti, P Cipriani, V Liakouli, D Iacono, I Pantano, DPE Margiotta, ... Clinical and Experimental Rheumatology 39 (5), 995-1002, 2020 | 19 | 2020 |
| Intravenous immunoglobulin therapy: a snapshot for the internist G Vitiello, G Emmi, E Silvestri, G Di Scala, B Palterer, P Parronchi Internal and Emergency Medicine 14 (7), 1041-1049, 2019 | 16 | 2019 |
